Brief: Dextech Medical Announces Positive Results From The Myeloma Study
Jan 23 (Reuters) - Dextech Medical AB DEXTECH.TE :
* ANNOUNCES POSITIVE RESULTS FROM THE MYELOMA STUDY
* BASELINE VALUE FOR CTX DECREASES BY ABOUT 80% AFTER 3
DOSES OF
OSTEODEX
* STUDY IS EXPECTED TO BE COMPLETED IN Q4, 2024
Source text for Eikon: ID:nWkr3HQK5W
Further company coverage: DEXTECH.TE
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Dextech Medical AB
See all newsSwedish drug developer DexTech's Q4 operating loss widens; reports positive patient outcomes
Brief: DexTech Q4 Operating Profit SEK -1.9 Million
Sweden's DexTech Q3 loss widens, OsteoDex drug study shows favorable safety profile
Brief: DexTech Q3 Operating Profit SEK -1.7 Million
Brief: DexTech Q4 Operating Profit SEK -1.6 Million